TNGX - Tango Therapeutics, Inc. Stock Price, Fair Value and News

9.75USD-0.10 (-1.02%)Market Closed

Market Summary

USD9.75-0.10

Market Closed

-1.02%

TNGX Alerts

2 major insider sales recently.

TNGX Stock Price

View Fullscreen

TNGX RSI Chart

TNGX Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

-9.32

Price/Sales (Trailing)

27.95

EV/EBITDA

-9.67

Price/Free Cashflow

-8.53

TNGX Price/Sales (Trailing)

TNGX Profitability

EBT Margin

-299.41%

Return on Equity

-42.22%

Return on Assets

-27.48%

Free Cashflow Yield

-11.73%

TNGX Fundamentals

TNGX Revenue

Revenue (TTM)

37.2M

Rev. Growth (Yr)

12.23%

Rev. Growth (Qtr)

19.15%

TNGX Earnings

Earnings (TTM)

-111.7M

Earnings Growth (Yr)

-35.37%

Earnings Growth (Qtr)

-23.25%

Breaking Down TNGX Revenue

Last 7 days

5.2%

Last 30 days

9.9%

Last 90 days

31.1%

Trailing 12 Months

232.8%

How does TNGX drawdown profile look like?

TNGX Financial Health

Current Ratio

8.23

TNGX Investor Care

Shares Dilution (1Y)

21.02%

Diluted EPS (TTM)

-1.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	37.2M	0	0	0
2023	24.9M	33.7M	37.5M	36.5M
2022	36.4M	24.0M	24.2M	24.9M
2021	18.8M	29.9M	31.6M	37.0M
2020	0	0	0	7.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

CEO	Dr. Barbara L. Weber M.D.
WEBSITE	tangotx.com
INDUSTRY	Biotechnology
EMPLOYEES	110

Tango Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Tango Therapeutics, Inc.? What does TNGX stand for in stocks?

TNGX is the stock ticker symbol of Tango Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tango Therapeutics, Inc. (TNGX)?

As of Fri Jul 26 2024, market cap of Tango Therapeutics, Inc. is 1.04 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNGX stock?

You can check TNGX's fair value in chart for subscribers.

Is Tango Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TNGX is over valued or under valued. Whether Tango Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Tango Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNGX.

What is Tango Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, TNGX's PE ratio (Price to Earnings) is -9.32 and Price to Sales (PS) ratio is 27.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNGX PE ratio will change depending on the future growth rate expectations of investors.